Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product is solithromycin (CEM-101) is for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin is active against many key CABP pathogens as well as against pneumococcal strains resistant to other macrolides. The product is in Phase III clinical trials. The Company’s Taksta is an antibiotic used for the long term oral treatment of prosthetic joint infections (PJI), caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus (MRSA). The product has completed the Phase II clinical trials.